trending Market Intelligence /marketintelligence/en/news-insights/trending/h755YVJ04e2Q25r2LysfYA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly to offer lower-priced versions of 2 Humalog-branded insulin products

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lilly to offer lower-priced versions of 2 Humalog-branded insulin products

Eli Lilly and Co. will offer lower-priced versions of two of its branded insulin products.

Versions of Humalog Mix75/25 KwikPen and Humalog Junior will be available by mid-April, at half the price of the branded products.

The lower-priced version of Humalog Mix75/25 will be called insulin lispro protamine and insulin lispro injectable suspension Mix75/25 KwikPen.

Meanwhile, the lower-priced version of Humalog Junior KwikPen will be known as insulin lispro injection junior KwikPen.

The cost-effective insulins, which are identical molecules to the branded products, will have a list price of $265.20 for one pack of five KwikPens, the Indianapolis-based pharmaceutical company said.

Eli Lilly said it will negotiate with wholesalers and payers to make the additional lower-priced insulins available.

The company, which launched its first low-priced insulin in May 2019, also said about 10% of Humalog users have transitioned to the less expensive version.

The high prices of insulin, a product essential for diabetes patients, have been the subject of a number of congressional hearings in the U.S.